Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia – a study on behalf of the Chronic Malignancies Working Party of the EBMT

Authors

Joanna Drozd-Sokolowska,[1] Luuk Gras,[2] Laurien G.A. Baaij,[2] Linda Koster,[2] Emma Nicholson,[3] Peter Dreger,[4] Tobias Gedde-Dahl,[5] Stephan Mielke,[6] Urpu Salmenniemi,[7] Grzegorz Basak,[1] Patrice Chevallier,[8] Gerald. G. Wulf,[9] Johannes Schetelig,[10] Jan-Erik Johansson,[11] Arnon Nagler,[12] Stephanie Nguyen Quoc,[13] Victoria Potter,[14] Elisa Sala,[15] Anna Bergendahl Sandstedt,[16] Yener Koc,[17] Robert Zeiser,[18] Michel van Gelder,[19] Wieslaw Wiktor Jedrzejczak,[1] Kavita Raj,[20] Donal P. McLornan[20] and Olivier Tournilhac[21]

[1]University Clinical Center, Medical University of Warsaw, Warsaw, Poland; [2]EBMT Leiden Study Unit, Leiden, the Netherlands; [3]Royal Marsden Hospital, London, UK; [4]University of Heidelberg, Heidelberg, Germany; [5]Oslo University Hospital, Rikshospitalet, Oslo, Norway; [6]Karolinska University Hospital, Stockholm, Sweden; [7]HUCH Comprehensive Cancer Center, Helsinki, Finland; [8]CHU Nantes, Nantes, France; [9]Universitaetsklinikum Goettingen, Goettingen, Germany; [10]Universitaetsklinikum Dresden, Dresden, Germany; [11]Sahlgrenska University Hospital, Goeteborg, Sweden; [12]Chaim Sheba Medical Center, Tel-Hashomer, Israel; [13]Universite Paris IV, Hopital la Pitié-Salpêtrière, Paris, France; [14]King's College Hospital London, London, UK; [15]Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; [16]University Hospital, Linkoeping, Linkoeping, Sweden; [17]Medicana International Hospital Istanbul, Istanbul, Turkey; [18]University of Freiburg, Freiburg, Germany; [19]Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands; [20]University College London Hospitals NHS Trust, London, UK and [21]CHU Estaing, Clermont-Ferrand University Hospital, Université Clermont Auvergne, EA7453 Chelter and CIC-1405, Clermont-Ferrand, France

Correspondence:
J. DROZD-SOKOŁOWSKA - Joanna.drozd-sokolowska@wum.edu.pl

https://doi.org/10.3324/haematol.2025.288819

Received: August 9, 2025.
Accepted: April 13, 2026.
Early view: April 23, 2026.

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

Supplemental Table S1: Additional patients' and transplantations' characteristics on TBI implementation in conditioning.

	Whole group	No TBI	TBI 2-4 Gy	TBI ≥6 Gy	Unknown TBI dose
	N (%)	N (%)	N (%)	N (%)	N (%)
Total	77	42	4	20	11
Myeloablative Conditioning	**38 (51.4)**	**14 (33.3)**		**16 (80.0)**	**8 (100.0)**
BuCy +/- others	1 (1.4)	1 (2.4)			
FluBu +/- others	1 (1.4)	1 (2.4)			
TBI +/- Cy +/- others	24 (32.4)			16 (80.0)	8 (100.0)
Others	12 (16.2)	12 (28.6)			
Reduced Intensity Conditioning	**36 (48.6)**	**28 (66.7)**	**4 (100.0)**	**4 (20.0)**	
FluBu +/- others	4 (5.4)	4 (9.5)			
FluMel +/- others	13 (17.6)	13 (31.0)			
FluTreo +/- others	1 (1.4)	1 (2.4)			
TBI +/- Cy +/- Flu +/- others	8 (10.8)		4 (100.0)	4 (20.0)	
Others	10 (13.5)	10 (23.8)			
Intensity description missing	*3*				*3*

Supplemental Table S2:

Univariable analysis of probability of overall survival (OS) and progression free survival (PFS) and cumulative non-relapse mortality (NRM) incidence and relapse incidence (RI) at 6 years after allo-HCT with (95% confidence intervals). The probabilities of OS and PFS were obtained using Kaplan-Meier methods and cumulative incidence of NRM and RI was obtained using the crude cumulative incidence estimator. P-values measure the probability that curves are similar (so do not just compare the 6-year estimates) and were obtained with the log-rank test for OS and PFS, Gray's test for NRM and RI and censoring events after 10 years. Analysis of post-transplant variables was done using a 100-day and 1-year landmark models for acute graft-versus-host disease (aGvHD) and chronic graft-versus-host disease (cGvHD), respectively. CI: confidence interval; CR: complete response; TBI: total body irradiation,. ALZ: alemtuzumab. Pt: patients, Dr: donors. Conso: consolidation.

Multivariable analysis (MVA). Estimates were obtained using Cox (cause-specific) proportional hazards models for overall survival (OS), progression free survival (PFS), risk of non-relapse mortality (NRM) and risk of relapse.

Univariable analysis									
						6-Year			
		OS (95% CI)	***P***	**PFS (95% CI)**	***P***	**NRM (95% CI)**	***P***	**RI (95% CI)**	***P***
All patients		29 (18-39)		20 (10-29)		38 (27-49)		42 (31-54)	
Pre-transplant variables									
Age at allo-HCT			0.31		0.46		0.44		0.22
	<50 y.	24 (7-40)		12 (0-25)		35 (16-53)		53 (34-73)	
	50-60 y.	28 (13-44)		25 (10-40)		45 (28-61)		30 (15-46)	
	≥60 y.	39 (14-65)		26 (2-49)		27 (4-51)		47 (21-73)	
Sex			0.21		0.23		0.18		0.59
	Male	24 (12-36)		16 (5-26)		44 (30-58)		40 (27-54)	
	Female	40 (18-61)		29 (9-50)		24 (5-42)		47 (25-69)	
Year of allo-HCT			**0.04**		0.11		**0.01**		0.16
	<2005	14 (0-28)		9 (0-21)		59 (39-80)		32 (12-51)	
	≥2005	35 (22-49)		25 (13-38)		29 (16-41)		46 (32-60)	
Conso. post ALZ 1st line			0.29		0.82		0.11		0.13
	yes	43 (24-62)		24 (7-40)		23 (7-39)		53 (34-72)	
	other	34 (12-57)		28 (7-50)		38 (15-60)		34 (12-57)	
ALZ single agent 1st line			0.66		0.90		0.07		0.09
	yes	45 (22-68)		23 (4-43)		16 (0-33)		60 (38-83)	
	no	35 (16-53)		26 (8-44)		38 (20-57)		36 (17-55)	
Previous lines of therapy			0.44		0.85		0.63		0.72
	1 line	40 (23-58)		24 (9-39)		30 (13-46)		46 (28-64)	
	≥2 lines	37 (11-63)		29 (4-54)		27 (4-49)		44 (17-71)	
Karnofsky score at HCT			0.05		0.09		0.71		0.56
	≤80%	27 (1-54)		18 (0-41)		36 (8-65)		45 (16-75)	
	90-100%	48 (28-68)		31 (12-50)		32 (13-50)		38 (18-57)	
Interval diagnosis-HCT			0.98		0.68		0.62		0.48
	<12 m.	29 (15-42)		22 (9-34)		40 (26-55)		38 (24-52)	
	≥12 m.	29 (11-47)		16 (0-32)		36 (17-55)		48 (30-67)	
Disease status at allo-HCT			**0.008**		**0.01**		0.42		0.55
	CR	48 (30-65)		33 (15-50)		27 (12-42)		41 (22-59)	
	Other	18 (5-30)		12 (2-23)		38 (22-53)		50 (34-66)	
Donor type			0.42		0.53		0.49		0.25
	MRD	36 (20-52)		24 (9-39)		41 (24-57)		35 (19-51)	
	Other	22 (8-36)		16 (4-29)		36 (20-51)		48 (32-64)	
Age of donor			0.20		0.40		0.05		0.26
	<45 y.	20 (5-36)		13 (0-26)		51 (32-69)		37 (19-55)	
	≥45 y.	43 (24-62)		28 (10-45)		23 (7-39)		49 (30-69)	
Conditioning intensity			0.55		0.67		0.38		0.25
	Standard	27 (13-42)		24 (10-39)		41 (25-57)		35 (20-50)	
	Reduced	33 (17-49)		16 (2-30)		29 (14-44)		55 (37-73)	
TBI in conditioning			0.15		**0.03**		0.36		**0.009**
	≥6 Gy	41 (18-64)		42 (19-65)		43 (20-67)		57 (42-72)	

	no / low dose	27 (14-40)		12 (2-22)		31 (18-45)		15 (0-31)	
Source of stem cells			0.47		0.17		0.61		0.08
	BM	36 (8-65)		36 (8-65)		45 (16-75)		18 (0-41)	
	PB	28 (16-39)		17 (7-27)		36 (24-48)		47 (34-60)	
CMV Serostatus (Pt/Dr) (-): negative (+): positive			0.07		0.11		0.12		0.32
	- / -	14 (0-33)		7 (0-21)		43 (17-69)		50 (24-76)	
	- / +	33 (0-71)		33 (0-71)		33 (0-71)		33 (0-71)	
	+ / -	36 (11-61)		29 (5-52)		50 (24-76)		21 (0-43)	
	+ / +	58 (33-82)		30 (5-55)		13 (0-31)		57 (30-83)	
Post-transplant variables									
aGvHD at 100 days			0.20		0.65		0.28		0.55
	no	39 (25-54)		29 (14-43)		28 (14-42)		47 (31-63)	
	yes	26 (3-48)		18 (0-40)		39 (14-64)		42 (18-67)	
cGvHD at 1 year			0.58		0.67		0.33		0.19
	no	43 (21-64)		38 (15-61)		34 (12-56)		28 (7-49)	
	yes	63 (42-85)		42 (17-67)		11 (0-26)		47 (22-72)	

Multivariable analysis (MVA)

		OS		**PFS**		**NRM**		**Relapse**	
		HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*	HR (95% CI)	*P*
TBI									
	low dose/no TBI	1.0		1.0		1.0		1.0	
	≥6 Gy	0.49 (0.25-0.97)	***0.04***	0.37 (0.19-0.73)	***0.004***	0.77 (0.31-1.90)	*0.57*	0.17 (0.06-0.51)	***0.002***
Age at allo-HCT (per 10 year older)		0.77 (0.57-1.04)	*0.08*	0.74 (0.55-0.99)	***0.04***	0.87 (0.55-1.36)	*0.54*	0.60 (0.40-0.91)	***0.02***
Year of allo-HCT (per year later)		0.97 (0.87-1.08)	*0.59*	0.98 (0.88-1.08)	*0.64*	0.95 (0.82-1.10)	*0.50*	1.00 (0.87-1.15)	*0.98*
Disease status at allo-HCT									
	CR	0.53 (0.29-0.97)	***0.04***	0.50 (0.28-0.89)	***0.02***	0.54 (0.22-1.30)	*0.17*	0.45 (0.21-0.96)	***0.04***
	Other	1.0		1.0		1.0		1.0	

HR: hazard ratio; CI: confidence interval; CR: complete response; TBI: total body irradiation

Figure legends

Supplemental Figure S1 Graft versus host disease (GvHD). Cumulative incidence of a**)** acute, and b) chronic GvHD. The number below the graph show the number of patients at risk for an event. The individual cumulative incidence curves are stacked on top of each other.

Supplemental Figure S1

